EraCal Therapeutics

EraCal Therapeutics Ltd., a preclinical biotech company and spin-off from the University of Zurich and Harvard University, is developing first-in-class drugs for various diseases. EraCal’s phenotypic drug discovery platform enables unbiased, large-scale in vivo drug discovery in zebrafish larvae. *Science Advances* published part of EraCal’s translational proof-of-concept. This phenotypic strategy allows for the identification of novel mechanisms of action, making it the preferred approach for discovering first-in-class drugs.